Non Interventional Post Marketing Programme in Acromegaly
Non Interventional Post Marketing Programme in Acromegaly
The purpose of this study, is to assess the safety and local tolerability of the long-term
 use of Somatuline Autogel when administered by patients or their partners ("Home Injection
 Group") and the safety and local tolerability in patients receiving their injection from a
 healthcare professional (HCP) ("Reference Group").
Inclusion Criteria:

 -  The patient must give written (personally signed and dated) informed consent for their
 data to be included in the database for this post-marketing surveillance programme and
 any subsequent analysis.

 -  The patient must have been receiving treatment with Somatuline Autogel at a stable
 dose for at least 4 months.

 -  The patient must have a diagnosis of acromegaly.

 -  The patient must be at least 18 years of age.

 -  For patients receiving or intending to receive Somatuline Autogel by home injection:

 -  The patient must be able to store Somatuline Autogel safely in a refrigerator in
 their own home and either collect it from their general practitioner/pharmacy on
 a monthly basis, or receive the medication by a home delivery service.

 Exclusion Criteria:

 -  The patient is pregnant or breast-feeding, unless continued treatment with Somatuline
 Autogel is clearly needed (as determined by the treating clinician).